This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mårtenson, E. D. Articles by Hansson, J. Search for Related Content PubMed PubMed Citation Articles by Mårtenson, E. D. Articles by Hansson, J.

Serum S-100B Protein as a Prognostic Marker in Malignant Cutaneous Melanoma

From the Departments of Oncology, Clinical Chemistry, and Cancer Epidemiology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.

Address reprint requests to Eva Djureen Mårtenson, Radiumhemmet, Karolinska Hospital, S-171 76 Stockholm, Sweden; email: evadj{at}rah.ks.se

PURPOSE: To evaluate whether S-100B protein in serum is an independent prognostic marker in malignant melanoma.

MATERIALS AND METHODS: S-100B protein in serum was analyzed in 1,007 consecutive patients with histologically verified cutaneous malignant melanoma. At the time of blood sampling, 876 patients were in clinical stage I, 35 were in stage II, and 96 were in stage III. The serum concentrations of S-100B protein were measured by a luminescence immunoassay (LIA).

RESULTS: The mean serum concentration of S-100B protein was significantly related to clinical stage, with the lowest level in stage I and the highest in stage III. In a multivariate analysis, S-100B protein levels in serum showed the strongest prognostic impact of the factors analyzed with respect to disease-specific survival in clinical stages II to III, followed by clinical stage. Serum S-100B protein was not a significant independent prognostic factor in clinical stage I, where tumor thickness showed the strongest relation to melanoma-specific survival, followed by ulceration and satellites.

CONCLUSION: This investigation contains the largest material of patients so far analyzed with the new LIA assay of S-100B protein in serum and confirms that S-100B protein in serum is correlated with clinical stage and is an independent prognostic marker in clinical stages II and III.

S-100B protein analysis kits were provided by Sangtec Medical, Bromma, Sweden.

This article has been cited by other articles:

				H. Schmidt, J. S. Johansen, P. Sjoegren, I. J. Christensen, B. S. Sorensen, K. Fode, J. Larsen, and H. von der Maase Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma J. Clin. Oncol., February 10, 2006; 24(5): 798 - 804. [Abstract] [Full Text] [PDF]

				A. Larsson, M. Lipcsey, J. Sjolin, L.-O. Hansson, and M. B. Eriksson Slight Increase of Serum S-100B During Porcine Endotoxemic Shock May Indicate Blood-Brain Barrier Damage Anesth. Analg., November 1, 2005; 101(5): 1465 - 1469. [Abstract] [Full Text] [PDF]

				G. S. O. A. Missotten, N. E. M. L. Tang, C. M. Korse, H. M. H. Hurks, D. de Wolff-Rouendaal, J. E. E. Keunen, M. J. Jager, and J. M. G. Bonfrer Prognostic Value of S-100-{beta} Serum Concentration in Patients With Uveal Melanoma Arch Ophthalmol, August 1, 2003; 121(8): 1117 - 1119. [Abstract] [Full Text] [PDF]

				G. Sorci, F. Riuzzi, A. L. Agneletti, C. Marchetti, and R. Donato S100B Inhibits Myogenic Differentiation and Myotube Formation in a RAGE-Independent Manner Mol. Cell. Biol., July 15, 2003; 23(14): 4870 - 4881. [Abstract] [Full Text] [PDF]